Search results
New chemotherapy approach for treating stomach cancer
Medical Xpress· 5 days agoStomach cancer is caused by an uncontrolled growth of cells that starts in the stomach. Most stomach...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 1 day agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Scaling back cancer treatment can help some patients without compromising outcomes, studies find
Euronews via Yahoo News· 1 day agoIt's part of a trend of studying whether less surgery, chemotherapy, and radiation can help patients...
New Manchester research centre aims to revolutionise treatment
BBC News· 2 hours agoThe work of a "revolutionary" new research centre could lead to some cancer patients avoiding...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Morningstar· 4 days agoInvestigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease ...
Cancer patients often do better with less intensive treatment, new research finds
WSB Radio· 2 days agoScaling back treatment for three kinds of cancer can make life easier for patients without...
'I'd be dead by now': Canadians share breast cancer stories as new screening guidelines spark...
Yahoo Canada Style· 4 hours agoAlthough a federal task force says mammograms shouldn't be routine for women under 50, new data...
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 1 day agoBristol Myers Squibb & Co BMY announced on Saturday (June 1) results from the Phase 3 KRYSTAL-12...
Trial suggests chemo before, after surgery could help those battling esophageal cancer
Medical Xpress· 7 hours ago"There is considerable disagreement as to whether giving all adjuvant [chemo] therapy upfront versus...
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on...
Morningstar· 3 days agoSeparate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.